Patent disputes endanger patients in Canadian drug market
The AMA warns Neo Cortef and NeoDecadron may be hazardous and lack proven effectiveness. The patent law battle between Canadian drug firms and the government spurs generic copies, potentially risking consumer safety amid rising drug costs and limited research incentives.
MENTIONED IN THIS ARTICLE
American Medical Association
AMA
United States
U.S. Food and Drug Administration
FDA
Canada
Federal Department of Corporate Affairs
Bill Robson
SmithKline and
Drug Copying in Canada Spurs Debate on Profits and Safety
A Southam News report analyzes how generic drug makers in Canada, led by PMAC members Novopharm and Apotex, press for longer patent protections while arguing outdated drugs keep prices down. Regulators lack full safety oversight, and profits drive both industry and government cost controls, with 1978 copied drug sales around $10 million of $714 million.
MENTIONED IN THIS ARTICLE
FDA
Montreal Gazette
Richard Graham
Federal Health Department
Human Prescription Drug Bureau
Ottawa
Canada
Economic Council of Canada
Pharmaceutical Manufacturers Association of Canada
PMAC
Federal
Department of Consumer and Corporate Affairs
Department of Health and Welfare
Novopharm
Frank W. Horner
Apotex
ICN
Guy Beauchemin
J. R. Fraser
Dan
Lee McCabe
Federal Department of Consumer and Corporate Affairs
Beauchemin
Pmac Company
Savory buns for holiday parties with simple fillings
A compact recipe for savory buns yields 30, using a yeast dough filled with options like paté or marinated mushrooms. The guide covers mixing, kneading 8 to 10 minutes, rising about 1 hour, shaping into 2 1/2 inch rounds, filling, sealing, decorating, baking at 400 F for 10 to 12 minutes, yielding 2 1/2 dozen buns.
Also Mentioned on This Page
Nicholas Regush
French Canada Ltd
Leslie Dan
Novo- Pharm
U.S
Canadian Institute For Economic Policy
The
Montréal Gazette
Southam News
Drug Enforcement Agency
Fleischmanns
AMET
Fleischmann
Wbn
Labis
Fleischmar
Chase
Fleischmann's